Detalhe da pesquisa
1.
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
Antimicrob Agents Chemother
; 68(1): e0095323, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38047645
2.
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
EBioMedicine
; 82: 104203, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915046